Please login to the form below

Not currently logged in
Email:
Password:

Lilly bolsters its oncology team

Kimberly Blackwell is appointed VP early phase development, immuno-oncology

Eli Lilly and Company has strengthened its oncology team with the addition of Kimberly Blackwell, who joins the pharma group as its new vice president of early phase development and immuno-oncology.

Blackwell currently serves as a professor of medicine and assistant professor of radiation oncology at Duke University Medical Center, and she is also the co-director of the Duke women’s cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles.

Sue Mahon, senior vice president and president of Lilly Oncology, said: “We are pleased and honoured to welcome Dr Blackwell to Lilly, she is a highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory approvals.

“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”

15th January 2018

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics